



Antibiotic resistance in *Helicobacter pylori* is a risk to human health

- *Helicobacter pylori* (*H. pylori*) is one of the most common bacterial infections worldwide and is closely associated with the incidence of chronic gastritis, peptic ulcers, and gastric cancer
- Current Management of *H. pylori* is based on a unified first line antibiotic treatment followed by second, and third-line treatment in case of eradication failure.
- The extent of eradication failure is estimated to be as high as 30%
- Eradication failure results mainly due to the bacteria resistance to the recommended antibiotic treatment regimen

Savvygen *H. pylori* & Antibiotic Resistance

A First Line Screening RT-PCR Assay for *H. pylori* and its resistance to Clarithromycin from Stool Specimens


- Non-Invasive Test, minimizes patient discomfort
- Allows for optimal antibiotic treatment and better management of *H. pylori*
- Reduces Misuse of Antibiotics

First line antibiotic resistance test is recommended by the Maastricht Consensus Group

Savvygen H. pylori & Antibiotic Resistance

Savvygen H. pylori & Antibiotic Resistance test is a qualitative molecular test for the identification of H. pylori bacteria and 3 mutations related to its antibiotic resistance to Clarithromycin (A2142C, A2142G, A2143G) from stool samples of symptomatic patients.

Work flow



High throughput work flow

- Automated extraction and PCR setup
- Automated interpretation with user-friendly interphase



Fast

96 samples within 2.5 hours



Accurate

- Sensitivity 98%
- Specificity 100%

